<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02987686</url>
  </required_header>
  <id_info>
    <org_study_id>CE16.221</org_study_id>
    <nct_id>NCT02987686</nct_id>
  </id_info>
  <brief_title>Topical Infliximab for Sterile Corneal Melt</brief_title>
  <official_title>Topical Infliximab for the Treatment of Sterile Corneal Melt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds de recherche en ophtalmologie de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal melt is a complication that could affect very ill eyes and lead to the thinning of&#xD;
      the cornea (the clear window covering of the eyes). This thinning can lead to severe&#xD;
      consequences such as the leakage of the liquid inside the eye (ocular perforation), or even&#xD;
      blindness. Corneal melt can be caused by certain infections or as a sterile process. This&#xD;
      project only includes patients with a sterile corneal melt (without an infection) caused by&#xD;
      diseases such as rosacea, Sjogren's syndrome, rheumatoid arthritis, Crohn's disease, Stevens&#xD;
      Johnson syndrome, as well as toxic epidermal necrolysis or mucous membrane pemphigoid.&#xD;
&#xD;
      Infliximab is an antibody against tumour necrosis factor alpha and has been used to treat or&#xD;
      prevent corneal melt in certain patients with inflammatory of auto-immune disease. In this&#xD;
      situation, infliximab was used intravenous (using veins) in order to treat the whole body.&#xD;
&#xD;
      This study's hypothesis is that infliximab can safely be used as eye drops for the treatment&#xD;
      of sterile corneal melt.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an unmasked, prospective, single-center trial of twelve patients with sterile corneal&#xD;
      melt and an underlying auto-immune or inflammatory disease, such as rosacea, Sjogren's&#xD;
      syndrome, rheumatoid arthritis, Crohn's disease, Stevens Johnson syndrome, as well as toxic&#xD;
      epidermal necrolysis or mucous membrane pemphigoid.&#xD;
&#xD;
      The aim of this phase I study is to evaluate the safety and tolerability of topical&#xD;
      infliximab 10mg/ml eye drops for the treatment of corneal melt. As such, six (6) subjects&#xD;
      will be recruited in the experimental treatment study and six (6) subjects will be enrolled&#xD;
      in the parallel observational study. Indeed, candidates having all inclusion criteria but one&#xD;
      exclusion criteria (which are contraindication to infliximab use), will be recruited in the&#xD;
      observational study, will receive the standard treatment without infliximab.&#xD;
&#xD;
      During the treatment period, subjects in the therapeutic study will receive topical&#xD;
      infliximab 10mg/ml four (4) times per day for four (4) weeks. In order to determine the&#xD;
      safety profile, potential side effects as well as the course of the disease, subjects will be&#xD;
      monitored while on the study medication as well as for 8 weeks following discontinuation of&#xD;
      the drug. The ophthalmological follow-up will be identical in the two groups. However, only&#xD;
      subjects enrolled in the experimental treatment study will receive additional laboratory&#xD;
      tests. The total study duration for each patient will be 12 weeks.&#xD;
&#xD;
      In terms of statistical analysis, the investigators will focus on describing the outcome&#xD;
      measured in the study. For instance, the investigators will describe the number and&#xD;
      proportion of side effects, the number of patients with a quiescent corneal melt at 4 weeks&#xD;
      and the patients who required a tectonic surgery at 12 weeks post-treatment. The&#xD;
      investigators will report the average and standard of deviation of the OSDI score, the&#xD;
      epithelial deficit surface as well as the minimal corneal thickness. Moreover, the&#xD;
      investigators will perform exploratory statistical analysis in order to study the disease&#xD;
      course of each subject and comparing the addition of infliximab to the standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number and type of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients finishing 4 weeks of infliximab use</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of patients finishing 4 weeks of infliximab use</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Visual Acuity is measured using a Snellen chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular surface symptoms as assessed by ocular disease index score</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Ocular surface symptoms as assessed by ocular disease index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival hyperemia using a slit-lamp photographs</measure>
    <time_frame>4 and 12 weeks</time_frame>
    <description>Conjunctival hyperemia using a slit-lamp photographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness as measured by anterior segment optical coherence tomography</measure>
    <time_frame>4 weeks</time_frame>
    <description>Corneal thickness as measured by anterior segment optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surface area of the corneal melt using a slit-lamp photographs</measure>
    <time_frame>4 weeks</time_frame>
    <description>Surface area of the corneal melt using a slit-lamp photographs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quiescent corneal state</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percentage of eyes presenting a quiescent corneal state at 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyes requiring tectonic surgery</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of eyes requiring tectonic surgery at 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Sterile Corneal Melt</condition>
  <arm_group>
    <arm_group_label>Topical Infliximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additionally to standard treatment, patients with all inclusive criteria and none exclusive criteria will be included in the therapeutic group and will receive topical infliximab QID for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with all inclusive criteria and one exclusive criteria will receive the standard treatment, without topical infliximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Infliximab</intervention_name>
    <description>Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.</description>
    <arm_group_label>Topical Infliximab</arm_group_label>
    <other_name>Remicade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years;&#xD;
&#xD;
          -  Any degree of active sterile corneal melting , as documented by slit-lamp examination,&#xD;
             showing an epithelial defect and stromal thinning;&#xD;
&#xD;
          -  Negative work-up for local and systemic infectious causes&#xD;
&#xD;
          -  Negative corneal cultures (may show growth of common contaminants)&#xD;
&#xD;
          -  Capable of providing informed consent;&#xD;
&#xD;
          -  Capable of administering eye drops either themselves or through a caregiver.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active ocular or systemic infection including active or latent tuberculosis,&#xD;
             histoplasmosis, coccidiomycosis, cytomegalovirus, pneumocystosis, aspergillosis, or&#xD;
             hepatitis B.&#xD;
&#xD;
          -  History of neoplasia diagnosed within the last 5 years&#xD;
&#xD;
          -  Demyelinating disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Significant anomalies on complete blood count, creatinine or hepatic enzymes&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Allergy to infliximab or to the drug vehicle (Refresh liquigel)&#xD;
&#xD;
          -  Past or present use of anti-TNF-α medications or human interleukin-1 receptor&#xD;
             antagonist (anakinra, IL-1Ra)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Claude Robert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier de l'Université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Claude Robert, MD</last_name>
    <phone>514 890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>marie-claude.robert.2@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Catherine Tessier</last_name>
    <phone>514 890-8000</phone>
    <phone_ext>11550</phone_ext>
    <email>marie-catherine.tessier.chum@ssss.gouv.qc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Catherine Tessier</last_name>
      <phone>5148908000</phone>
      <phone_ext>11550</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>December 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Topical Infliximab</keyword>
  <keyword>Cornea</keyword>
  <keyword>Keratolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Ulcer</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

